MaaT Pharma Aktie

5,80 EUR -0,02 EUR -0,34 %

13:58:01

STU

5,92 EUR +0,06 EUR +1,02 %

23.04.2025

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.95,40 Mio. EUR

Div. Rendite0,00%

WKNA3C7A5

ISINFR0012634822

SymbolMATPF

MaaT Pharma Aktien News

Sortieren:Datum Meistgelesen

08.01.25BusinesswireMaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease

10.12.24BusinesswireCORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

09.12.24BusinesswireMaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

WerbungMaaT Pharma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

05.12.24BusinesswireMaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

26.11.24BusinesswireMaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

07.11.24BusinesswireMaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

05.11.24BusinesswireMaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes

15.10.24BusinesswireMaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease

19.09.24BusinesswireMaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update

04.09.24BusinesswireMaaT Pharma To Present and Participate in Investor and Medical Conferences in September

02.07.24BusinesswireMaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

25.06.24BusinesswireMaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16

24.06.24BusinesswireMaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer

15.05.24BusinesswireMaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros

14.05.24BusinesswireMaaT Pharma Launches a Global Offering of approximately 18 Million Euros

07.05.24BusinesswireMaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

15.04.24BusinesswireMaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event

28.03.24BusinesswireMaaT Pharma Announces 2023 Annual Results and Provides a Business Overview

12.03.24BusinesswireMaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

29.02.24BusinesswireMaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

12.12.23BusinesswireMaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations

11.12.23BusinesswireMaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023

30.11.23BusinesswireMaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan

10.11.23finanzen.netMaaT Pharma: Bilanzvorlage zum letzten Quartal

09.11.23BusinesswireMaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

06.11.23BusinesswireMaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT

02.11.23BusinesswireMaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference

31.10.23BusinesswireMaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies

26.10.23BusinesswireMaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013

26.09.23BusinesswireMaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update

12.09.23BusinesswireMaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies

07.09.23BusinesswireMaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation

27.07.23BusinesswireMaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results

26.07.23BusinesswireMaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD

20.07.23BusinesswireMaaT Pharma Joins Microbiome Therapeutics Innovation Group

21.06.23BusinesswireMaaT Pharma Announces New Appointments to the Board and Executive Team

09.05.23BusinesswireMaaT Pharma Announces Cash and Revenues for the First Quarter of 2023

24.04.23BusinesswireMaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

11.04.23BusinesswireMaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting

30.03.23BusinesswireMaaT Pharma Announces 2022 Annual Results and Provides a Business Overview

MaaT Pharma News

MaaT Pharma News: auf dieser Seite finden Sie alle MaaT Pharma News und Nachrichten zur MaaT Pharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MaaT Pharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MaaT Pharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.